Binimetinib

比美替尼

Report date: 2026/04/28 20:00:22
NME

Base Information

Drug NameBinimetinib
Drug Alias Name贝美替尼Balimek比美替尼比尼替尼Mektovi +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 1 inhibitorsDual specificity mitogen-activated protein kinase kinase 2 inhibitors
TargetsDual specificity mitogen-activated protein kinase kinase 2Dual specificity mitogen-activated protein kinase kinase 1
Therapy Area/IndicationsUveal melanomaSolid tumoursMyelodysplastic Syndromes +[49] 
Global Approved IndicationsMelanoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2018/06/27
Country/TerritoryCzechiaBelgiumCanada +[43] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesArray Biopharma
China Registration ClassN/A

Develop Information

Active CompaniesPierre Fabre LaboratoriesUtah State UniversityDana-Farber Cancer Institute +[15] 
Inactive CompaniesYale UniversityH Lee Moffitt Cancer Center & Research InstituteThe University Of Texas MD Anderson Cancer Center +[4] 
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsProstatic Neoplasms +[33] 
Inactive IndicationsUveal melanomaMyelodysplastic SyndromesCardiomegaly +[16] 

Other Information

ATC CodeL01EE03
Related LinksWikipediaDrugBankKEGG